204 related articles for article (PubMed ID: 22996951)
1. The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy.
Legigan T; Clarhaut J; Tranoy-Opalinski I; Monvoisin A; Renoux B; Thomas M; Le Pape A; Lerondel S; Papot S
Angew Chem Int Ed Engl; 2012 Nov; 51(46):11606-10. PubMed ID: 22996951
[TBL] [Abstract][Full Text] [Related]
2. Prodrugs in cancer chemotherapy.
Connors TA; Knox RJ
Stem Cells; 1995 Sep; 13(5):501-11. PubMed ID: 8528099
[TBL] [Abstract][Full Text] [Related]
3. Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies.
Tietze LF; Krewer B
Chem Biol Drug Des; 2009 Sep; 74(3):205-11. PubMed ID: 19660031
[TBL] [Abstract][Full Text] [Related]
4. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
[TBL] [Abstract][Full Text] [Related]
5. Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue.
Chen KC; Schmuck K; Tietze LF; Roffler SR
Mol Pharm; 2013 May; 10(5):1773-82. PubMed ID: 23448264
[TBL] [Abstract][Full Text] [Related]
6. A prodrug nanoassembly entrapping drugs as a tumor-targeted delivery system.
Yuan Z; Yi X; Zhang J; Cheng S; Zhuo R; Li F
Chem Commun (Camb); 2013 Jan; 49(8):801-3. PubMed ID: 23235958
[TBL] [Abstract][Full Text] [Related]
7. PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites.
Wong BK; DeFeo-Jones D; Jones RE; Garsky VM; Feng DM; Oliff A; Chiba M; Ellis JD; Lin JH
Drug Metab Dispos; 2001 Mar; 29(3):313-8. PubMed ID: 11181501
[TBL] [Abstract][Full Text] [Related]
8. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer.
Connors TA
Gene Ther; 1995 Dec; 2(10):702-9. PubMed ID: 8750009
[TBL] [Abstract][Full Text] [Related]
9. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
Wallace PM; Senter PD
Methods Find Exp Clin Pharmacol; 1994 Sep; 16(7):505-12. PubMed ID: 7885077
[TBL] [Abstract][Full Text] [Related]
10. Duocarmycin-based prodrugs for cancer prodrug monotherapy.
Tietze LF; Schuster HJ; Schmuck K; Schuberth I; Alves F
Bioorg Med Chem; 2008 Jun; 16(12):6312-8. PubMed ID: 18524605
[TBL] [Abstract][Full Text] [Related]
11. Suicide gene therapy using E. coli beta-galactosidase.
Farquhar D; Pan BF; Sakurai M; Ghosh A; Mullen CA; Nelson JA
Cancer Chemother Pharmacol; 2002 Jul; 50(1):65-70. PubMed ID: 12111114
[TBL] [Abstract][Full Text] [Related]
12. [Immunoconjugates, drug-armed antibodies to fight against cancer].
Haeuw JF; Caussanel V; Beck A
Med Sci (Paris); 2009 Dec; 25(12):1046-52. PubMed ID: 20035677
[TBL] [Abstract][Full Text] [Related]
13. A galactosidase-responsive "trojan horse" for the selective targeting of folate receptor-positive tumor cells.
Thomas M; Clarhaut J; Strale PO; Tranoy-Opalinski I; Roche J; Papot S
ChemMedChem; 2011 Jun; 6(6):1006-10. PubMed ID: 21442760
[No Abstract] [Full Text] [Related]
14. Enzyme-catalyzed activation of anticancer prodrugs.
Rooseboom M; Commandeur JN; Vermeulen NP
Pharmacol Rev; 2004 Mar; 56(1):53-102. PubMed ID: 15001663
[TBL] [Abstract][Full Text] [Related]
15. Targeting cell surface alpha(v)beta(3) integrin increases therapeutic efficacies of a legumain protease-activated auristatin prodrug.
Liu Y; Bajjuri KM; Liu C; Sinha SC
Mol Pharm; 2012 Jan; 9(1):168-75. PubMed ID: 22044266
[TBL] [Abstract][Full Text] [Related]
16. An improved synthesis of lysosomal activated mustard prodrug for tumor-specific activation and its cytotoxic evaluation.
Adidala R; Devalapally H; Srivari C; Devarakonda R K; Akkinepally RR
Drug Dev Ind Pharm; 2012 Sep; 38(9):1047-53. PubMed ID: 22185667
[TBL] [Abstract][Full Text] [Related]
17. Asymmetric synthesis and biological evaluation of glycosidic prodrugs for a selective cancer therapy.
Tietze LF; von Hof JM; Krewer B; Müller M; Major F; Schuster HJ; Schuberth I; Alves F
ChemMedChem; 2008 Dec; 3(12):1946-55. PubMed ID: 19021160
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel prodrugs: toward smarter delivery of anticancer agents.
Skwarczynski M; Hayashi Y; Kiso Y
J Med Chem; 2006 Dec; 49(25):7253-69. PubMed ID: 17149855
[No Abstract] [Full Text] [Related]
19. Tumor targeting: activation of prodrugs by enzyme-monoclonal antibody conjugates.
Huennekens FM
Trends Biotechnol; 1994 Jun; 12(6):234-9. PubMed ID: 7765070
[TBL] [Abstract][Full Text] [Related]
20. Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT.
Tietze LF; Schmuck K
Curr Pharm Des; 2011; 17(32):3527-47. PubMed ID: 22074425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]